Publicaciones en las que colabora con José Luis Calleja Panero (28)

2023

  1. Alcohol-related liver disease phenotype impacts survival after an acute variceal bleeding episode

    Liver International, Vol. 43, Núm. 7, pp. 1548-1557

  2. Hepatic encephalopathy is not a contraindication to pre-emptive TIPS in high-risk patients with cirrhosis with variceal bleeding

    Gut, Vol. 72, Núm. 4, pp. 749-758

  3. Liver Transplantation for Porto-sinusoidal Vascular Liver Disorder: Long-term Outcome

    Transplantation, Vol. 107, Núm. 6, pp. 1330-1340

  4. Metabolomics as a tool to predict the risk of decompensation or liver-related death in patients with compensated cirrhosis

    Hepatology (Baltimore, Md.), Vol. 77, Núm. 6, pp. 2052-2062

  5. Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B

    Digestive Diseases and Sciences, Vol. 68, Núm. 6, pp. 2731-2737

2021

  1. Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis

    Journal of Hepatology, Vol. 75, Núm. 3, pp. 589-599

  2. Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis

    Journal of Hepatology, Vol. 75, Núm. 2, pp. 342-350

  3. Mild AST elevation as an early sign of COVID-19 severity in a multicenter Madrid cohort

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 113, Núm. 11, pp. 780-786

  4. Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis

    JHEP Reports, Vol. 3, Núm. 6

  5. Tacrolimus as an Effective and Durable Second-Line Treatment for Chronic Autoimmune Hepatitis: A Multicentric Study

    Digestive Diseases and Sciences, Vol. 66, Núm. 8, pp. 2826-2832

2020

  1. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension

    Journal of Hepatology, Vol. 73, Núm. 6, pp. 1415-1424

  2. Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in Patients With COVID-19

    The Journal of infectious diseases, Vol. 222, Núm. 5, pp. 726-733

  3. Management of chronic liver disease-associated severe thrombocytopenia in Spain: a view from the experts

    Revista Española de Enfermedades Digestivas, Vol. 112, Núm. 10, pp. 778-783

  4. Persistence of clinically significant portal hypertension after eradication of hepatitis C virus in patients with advanced cirrhosis

    Clinical Infectious Diseases, Vol. 71, Núm. 10, pp. 2726-2729

  5. Plasma metabolomic fingerprint of advanced cirrhosis stages among HIV/HCV-coinfected and HCV-monoinfected patients

    Liver International, Vol. 40, Núm. 9, pp. 2215-2227

  6. Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS

    Journal of Hepatology, Vol. 73, Núm. 5, pp. 1082-1091

2019

  1. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial

    The Lancet, Vol. 393, Núm. 10181, pp. 1597-1608

2017

  1. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort

    Journal of Hepatology, Vol. 66, Núm. 6, pp. 1138-1148

  2. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis

    Gastroenterology, Vol. 153, Núm. 5, pp. 1273-1283.e1

2016

  1. Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension

    Hepatology, Vol. 63, Núm. 1, pp. 197-206